Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Genomic Analysis Used to Diagnose Neurodevelopmental and Congenital Anomalies

By LabMedica International staff writers
Posted on 08 Apr 2019
A recent paper described the use of genomic DNA methylation analysis to facilitate the molecular diagnosis of unresolved clinical cases of neurodevelopmental and congenital anomalies (ND/CAs) and highlighted the potential value of epigenomic testing in the routine clinical assessment of these disorders.

Conventional analysis of sequence and copy number variants of individuals with ND/CAs leaves a substantial proportion of them unexplained. More...
Some of these cases have been shown to result from DNA methylation defects at a single locus (epi-variants), while others can exhibit syndrome-specific DNA methylation changes across multiple loci (epi-signatures).

Investigators at Lawson Health Research Institute (London, ON, Canada) evaluated the clinical diagnostic utility of genome-wide DNA methylation analysis of peripheral blood in unresolved ND/CAs. They generated a computational model enabling concurrent detection of 14 syndromes using DNA methylation data with full accuracy.

The investigators demonstrated the ability of this model in resolving 67 individuals with uncertain clinical diagnoses, some of who had variants of unknown clinical significance in the related genes. They showed that the provisional diagnoses could be ruled out in many of the case subjects, some of who were shown by the model to have other diseases initially not considered.

By applying this model to a cohort of 965 ND/CA-affected subjects without a previous diagnostic assumption and a separate assessment of rare epi-variants in this cohort, the investigators identified 15 case subjects with syndromic Mendelian disorders, 12 case subjects with imprinting and trinucleotide repeat expansion disorders, as well as 106 case subjects with rare epi-variants, a portion of which involved genes clinically or functionally linked to the subjects' phenotypes.

"Many families spend years going through repeated testing and assessments, in search of a diagnosis. This process is hard on patients and families, and is a great cost to our health care system," said senior author Dr. Bekim Sadikovic, head of the molecular genetics division at London Health Research Institute. "We are excited to make this testing accessible to local patients, and across the world. Our lab has partnered and licensed this technology to Greenwood Genetics Laboratories (Greenwood, SC, USA) in the United States and Amsterdam University Medical Centre Laboratories (The Netherlands) in the European Union."

Use of genomic DNA methylation analysis to diagnose unresolved ND/CA cases was described in the March 28, 2019, online edition of the journal American Journal of Human Genetics.

Related Links:
Lawson Health Research Institute
Greenwood Genetics Laboratories
Amsterdam University Medical Centre Laboratories


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PSA Assay
CanAg PSA EIA
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.